Business Context and Reporting Period
This Form 6-K filing by InflaRx N.V. is dated June 13, 2019. The company, headquartered in Jena, Germany, is a foreign private issuer reporting pursuant to Rule 13a-16 of the Securities Exchange Act of 1934. The filing serves to disseminate a press release regarding a clinical trial milestone.
Key Financial Metrics
The filing text does not provide a clear value for revenue, profit, cash flow, margins, debt, or liquidity. This report is a current event disclosure and does not contain financial statements or quantitative financial data.
Material Changes
The material change reported is a clinical development milestone rather than a financial variance. On June 13, 2019, InflaRx treated the first patient in a Phase IIa clinical trial with its lead candidate, IFX-1, for the treatment of Pyoderma Gangraenosum.
Outlook, Risks, and Management Commentary
Management commentary is limited to the announcement of the first patient treatment in the Phase IIa trial. The filing does not provide specific financial guidance, updated risk factors, or details on contingencies beyond the standard incorporation of the press release.
Investor Verification Checklist
- Verify the full text of the press release (Exhibit 99.1) for detailed trial design and patient eligibility criteria.
- Confirm the regulatory status of the Phase IIa trial for IFX-1 in Pyoderma Gangraenosum.
- Review subsequent filings for interim data readouts or safety updates from this trial.
- Check the company's cash runway in the most recent 20-F or 10-Q, as this filing contains no liquidity data.